Description
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm’s revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l’Etoile, France.
